Quarterly ResultAug 5, 2026, 04:11 PM
BioCryst Q2 Net Income $78.4M; H1 Net Loss $643.4M on Astria Acquisition
AI Summary
BioCryst Pharmaceuticals reported a net income of $78.4 million for Q2 2026, a significant increase from $5.1 million in Q2 2025. However, for the first six months of 2026, the company posted a net loss of $643.4 million, primarily due to a $697.8 million acquired in-process research and development expense related to the Astria Therapeutics acquisition. Total revenues for Q2 rose 33.6% to $218.3 million, and for H1 increased 21.3% to $374.7 million. The company also secured a new $400 million term loan.
Key Highlights
- Acquired Astria Therapeutics, Inc. on January 23, 2026, for $489.5 million cash and $251.7 million in common stock.
- Reported Q2 2026 net income of $78.4 million, up 1441.6% from $5.1 million in Q2 2025.
- Recorded H1 2026 net loss of $643.4 million, compared to net income of $5.1 million in H1 2025.
- H1 2026 net loss primarily driven by $697.8 million acquired in-process R&D expense from Astria acquisition.
- Q2 2026 total revenues increased 33.6% to $218.3 million; H1 2026 total revenues rose 21.3% to $374.7 million.
- Secured a new $400 million term loan, contributing to a cash and equivalents balance of $155.0 million.
- Net cash provided by operating activities for H1 2026 was $42.6 million, up 208.7% YoY.
Price Impact
More from BCRX